Need professional-grade analysis? Visit stockanalysis.com
$1.19B
N/A
N/A
N/A
Taysha Gene Therapies Inc (TSHA) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $6.22, down 3.27% from the previous close.
Over the past year, TSHA has traded between a low of $1.76 and a high of $6.43. The stock has gained 241.8% over this period. It is currently 253.4% above its 52-week low.
Taysha Gene Therapies Inc has a market capitalization of $1.19B.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Side-by-side comparison against top Healthcare peers.